Compare Amylx Pharmaceuticals Inc (AMLX) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Riot Platforms Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Riot Platforms Inc trades at $20.3 (market cap $7.59B). The key difference: Riot Platforms Inc is far larger — about 2.9× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Riot Platforms Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | RIOT | |
|---|---|---|
Market Cap | $2.64B | $7.59B |
Sector | Health | Technology |
52-Week High | $24.19 | $28.67 |
52-Week Low | $7.82 | $11.33 |
Enterprise Value | $2.39B | $8.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
RIOT Platforms trades at $20.32, up 4.74% today, amid strong technical resistance near $21-$23 levels. The stock shows bearish momentum despite recent positive news about a $9.1 billion AI infrastructure deal with Anthropic. Fundamentally, the company continues to post significant losses with a -196.28% net income margin, though revenue growth remains steady at $675 million projected for 2026.
While analyst consensus remains overwhelmingly bullish with a $33.40 price target, investors face substantial execution risks as RIOT transitions from bitcoin mining to AI infrastructure. The company's persistent negative cash flow and high valuation multiples present challenges despite the transformative potential of the Anthropic partnership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
